Jabbour E - Search Results

1

Gemtuzumab Ozogamicin is a promising post-remission therapy for acute myeloid leukemia.

El Kinge AR, Hatoum HA, Mahfouz RA, Otrock ZK, Jabbour E, Kantarjian H, Bazarbachi A. El Kinge AR, et al. Among authors: jabbour e. Leuk Res. 2009 Apr;33(4):565-6. doi: 10.1016/j.leukres.2008.05.006. Epub 2008 Jun 20. Leuk Res. 2009. PMID: 18571231 No abstract available.

2

Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: possible mechanisms of action.

Jabbour E, Kantarjian H, Cortes J. Jabbour E, et al. Leuk Lymphoma. 2004 Nov;45(11):2187-95. doi: 10.1080/10428190412331272677. Leuk Lymphoma. 2004. PMID: 15512806 Review.

3

Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate.

Jabbour E, Kantarjian H, O'Brien S, Rios MB, Abruzzo L, Verstovsek S, Garcia-Manero G, Cortes J. Jabbour E, et al. Blood. 2006 Jan 15;107(2):480-2. doi: 10.1182/blood-2005-05-1816. Epub 2005 Sep 29. Blood. 2006. PMID: 16195326 Free article.

4

Clinical experience with decitabine in North American patients with myelodysplastic syndrome.

Yee KW, Jabbour E, Kantarjian HM, Giles FJ. Yee KW, et al. Among authors: jabbour e. Ann Hematol. 2005 Dec;84 Suppl 1:18-24. doi: 10.1007/s00277-005-0019-7. Ann Hematol. 2005. PMID: 16273408

5

Adult acute lymphoblastic leukemia.

Jabbour EJ, Faderl S, Kantarjian HM. Jabbour EJ, et al. Mayo Clin Proc. 2005 Nov;80(11):1517-27. doi: 10.4065/80.11.1517. Mayo Clin Proc. 2005. PMID: 16295033 Review.

6

Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome.

Kantarjian H, O'brien S, Cortes J, Giles F, Faderl S, Jabbour E, Garcia-Manero G, Wierda W, Pierce S, Shan J, Estey E. Kantarjian H, et al. Among authors: jabbour e. Cancer. 2006 Mar 1;106(5):1090-8. doi: 10.1002/cncr.21723. Cancer. 2006. PMID: 16435386 Free article.

7

Adult acute myeloid leukemia.

Jabbour EJ, Estey E, Kantarjian HM. Jabbour EJ, et al. Mayo Clin Proc. 2006 Feb;81(2):247-60. doi: 10.4065/81.2.247. Mayo Clin Proc. 2006. PMID: 16471082 Review.

8

Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure.

Jabbour E, Cortes J, Kantarjian HM, Giralt S, Jones D, Jones R, Giles F, Andersson BS, Champlin R, de Lima M. Jabbour E, et al. Blood. 2006 Aug 15;108(4):1421-3. doi: 10.1182/blood-2006-02-001933. Epub 2006 Apr 6. Blood. 2006. PMID: 16601247 Free article.

9

Validation of the European Prognostic Index for younger adult patients with acute myeloid leukaemia in first relapse.

Giles F, Verstovsek S, Garcia-Manero G, Thomas D, Ravandi F, Wierda W, Ferrajoli A, Kornblau S, Jabbour E, Shan J, O'brien S, Albitar M, Kantarjian H. Giles F, et al. Among authors: jabbour e. Br J Haematol. 2006 Jul;134(1):58-60. doi: 10.1111/j.1365-2141.2006.06106.x. Br J Haematol. 2006. PMID: 16803568 Free article.

10

Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate.

Jabbour E, Kantarjian H, Jones D, Talpaz M, Bekele N, O'Brien S, Zhou X, Luthra R, Garcia-Manero G, Giles F, Rios MB, Verstovsek S, Cortes J. Jabbour E, et al. Leukemia. 2006 Oct;20(10):1767-73. doi: 10.1038/sj.leu.2404318. Epub 2006 Jul 20. Leukemia. 2006. PMID: 16855631

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

899 results

Search Page

Filters